查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1623496

2024 年至 2031 年肿瘤消融市场（按技术、应用和地区划分）

Tumor Ablation Market By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation), By Application (Liver Cancer, Lung Cancer, Kidney Cancer), & Region For 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年至 2031 年肿瘤消融市场评估

全球癌症发生率的不断上升以及微创治疗技术的进步推动了肿瘤消融的需求。肿瘤消融采用射频消融和微波消融等技术，为传统手术提供了替代方法，特别是对于无法接受手术介入的患者。预计这将推动肿瘤消融市场在 2023 年的收入超过 12 亿美元，并在 2031 年达到约 26 亿美元的估值。

肿瘤消融术已被证实具有精准瞄准和摧毁肿瘤细胞而不伤害周围组织的功效，目前已用于治疗肝臟、肺臟和肾臟等器官中的小肿瘤，颇受青睐。由于对微创手术和技术进步的需求不断增加，预计 2024 年至 2031 年期间市场复合年增长率将达到 12.9%。

肿瘤消融市场定义/概述

肿瘤消融是指一种微创手术，用于破坏癌细胞，而无需透过传统手术切除肿瘤。该技术使用各种形式的能量，包括射频、微波和冷冻消融，来破坏癌细胞。这些技术越来越多地被用于治疗多种类型的癌症，特别是对于那些因年龄、健康状况或肿瘤位置而不适合手术的患者。

肿瘤消融具有恢復时间更短、併发症更少、并且可以作为门诊手术进行的优点。它常用于治疗肝肿瘤、肺肿瘤、肾肿瘤和骨肿瘤。随着对个人化、微创治疗方案的需求不断增加，肿瘤消融市场的未来在于影像导引程序的进一步发展以及与免疫疗法和化学疗法等其他治疗方式的结合。

癌症发生率的增加会推动肿瘤消融市场的发展吗？

全球癌症发生率不断上升，尤其是肝癌、肺癌和肾癌，是肿瘤消融市场的主要驱动力。根据世界卫生组织 (WHO) 的数据，到 2040 年癌症患者数量预计将增加 47%，从而促使对治疗方案的需求增加。肿瘤消融因其微创性以及可以治疗不适合手术的患者而被广泛接受。

此外，人们越来越倾向于透过门诊手术减少住院时间和恢復时间，这进一步推动了肿瘤消融技术的采用。此外，由于医疗保健基础设施的改善和癌症意识的不断增强，新兴市场扩大采用消融技术，预计也将推动市场成长。

高昂的治疗费用和有限的先进技术取得管道是否会阻碍肿瘤消融市场的发展？

儘管肿瘤消融市场有许多好处，但它也面临着许多课题，包括治疗成本上升以及新兴地区获得先进技术的机会有限。肿瘤消融需要专门的设备和训练有素的专业人员，这使得治疗费用更高，在低收入地区更难获得治疗。这限制了医疗保健系统不发达地区肿瘤消融的普及。

此外，一些国家存在报销问题，为医疗保健提供者和患者带来重大课题。消融设备的高成本，加上保险覆盖的不一致，可能会阻止小型医院和诊所提供这些治疗，从而减缓市场成长。

目录

第 1 章 全球肿瘤消融市场简介

    市场概况
  • 研究范围
  • 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

  • 资料探勘
  • 验证
  • 主要来源
  • 资料来源列表

第 4 章 肿瘤消融的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 阻碍因素
    • 机会
  • 波特五力模型
  • 价值链分析

第5章 全球肿瘤消融市场（依技术划分）

  • 概述
  • 射频消融术 (RFA)
  • 微波消融 (MWA)
  • 冷冻消融
  • 其他技术

第6章 全球肿瘤消融市场（依应用）

  • 概述
  • 肝癌
  • 肺癌
  • 肾癌
  • 其他

第7章 全球肿瘤消融市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
    亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第 8 章全球肿瘤消融市场的竞争格局

  • 概述
  • 各公司的市场排名
  • 主要发展策略

第9章 公司简介

  • Healthtronics, Inc.
  • Medtronic, PLC.
  • Sonacare Medical, LLC
  • Boston Scientific Corporation
  • Edap Tms S.A.
  • Misonix, Inc.
  • Galil Medical, Inc.
  • Neuwave Medical, Inc.
  • Mermaid Medical A/S
  • Angiodynamics, Inc.

第 10 章附录

  • 相关研究
简介目录
Product Code: 23913

Tumor Ablation Market Valuation - 2024-2031

The growing prevalence of cancer worldwide, along with technological advancements in minimally invasive treatments, is driving the demand for tumor ablation procedures. Tumor ablation, which uses techniques like radiofrequency and microwave ablation, offers an alternative to traditional surgery, especially for patients unable to undergo surgical interventions. This has enabled the Tumor Ablation Market to exceed a revenue of USD 1.2 Billion in 2023 and is projected to reach a valuation of aroundUSD 2.6 Billion by 2031.

Tumor ablation is recognized for its precision in targeting and destroying tumor cells without harming surrounding tissues, making it a preferred choice for treating small tumors in organs like the liver, lungs, and kidneys. The market is expected to grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031 due to the increasing demand for minimally invasive procedures and technological advancements.

Tumor Ablation Market: Definition/ Overview

Tumor ablation refers to minimally invasive procedures used to destroy cancer cells without removing the tumor through traditional surgery. This technology uses different forms of energy, including radiofrequency, microwave, and cryoablation, to destroy cancer cells. These techniques are increasingly being used to treat various types of cancer, particularly in patients who are poor candidates for surgery due to age, health condition, or the tumor's location.

Tumor ablation offers several benefits including reduced recovery times, fewer complications, and the ability to perform the procedure on an outpatient basis. It is commonly used in treating liver, lung, kidney, and bone tumors. As demand for personalized, minimally invasive treatment options rises, the future of the Tumor Ablation Market lies in further advancements in image-guided procedures and integration with other treatment modalities like immunotherapy and chemotherapy.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Increasing Incidence of Cancer Drive the Tumor Ablation Market?

The rising global incidence of cancer, particularly liver, lung, and kidney cancers is a significant driver of the Tumor Ablation Market. According to the World Health Organization (WHO), cancer cases are expected to rise by 47% by 2040 leading to an increased demand for treatment options. Tumor ablation due to its minimally invasive nature and ability to treat patients who are not suitable for surgery is gaining widespread acceptance.

Moreover, the growing preference for outpatient procedures which reduce hospital stays and recovery times is further boosting the adoption of tumor ablation techniques. The increased adoption of ablation technologies in emerging markets driven by improved healthcare infrastructure and rising cancer awareness is also anticipated to fuel market growth.

Will High Treatment Costs and Limited Access to Advanced Technologies Hamper the Tumor Ablation Market?

Despite its benefits, the Tumor Ablation Market faces challenges including high treatment costs and limited access to advanced technologies in developing regions. Tumor ablation procedures require specialized equipment and trained professionals which can make these treatments costly and less accessible in low-income areas. This limits the adoption of tumor ablation in regions with less-developed healthcare systems.

Furthermore, reimbursement issues in several countries pose a significant challenge for healthcare providers and patients. The high cost of ablation equipment, combined with inconsistent insurance coverage, may deter smaller hospitals and clinics from offering these treatments, potentially slowing market growth.

Category-Wise Acumens

Will Radiofrequency Ablation Continue to Dominate the Tumor Ablation Market?

Radiofrequency ablation (RFA) remains the most widely used technology in tumor ablation due to its proven efficacy and safety. RFA works by generating heat to destroy cancer cells, and it is particularly effective in treating liver and lung tumors. As it offers precise control over the ablation area minimizing damage to surrounding tissues, it continues to be a preferred method in oncology. Meanwhile, microwave ablation is rapidly gaining popularity due to its ability to create larger ablation zones making it suitable for larger tumors. Cryoablation which involves freezing the tumor cells is also gaining traction, particularly in treating kidney and prostate cancers.

While RFA is expected to remain the primary treatment, new technologies like as microwave ablation (MWA) and cryoablation are gaining interest and may challenge its dominance. MWA has benefits such as quicker treatment periods and the potential to treat larger tumors which may be appealing to both physicians and patients. Similarly, cryoablation is being investigated for its unique capacity to freeze tumors which could offer an alternative for certain patient profiles. As these technologies progress and clinical evidence for their efficacy grows, they may acquire a sizable share of the tumor ablation industry.

Will the Increasing Adoption of Tumor Ablation in Liver Cancer Treatment Drive the Market?

Liver cancer is one of the most common cancers treated with tumor ablation, and this trend is expected to continue driving market growth. The rising incidence of liver cancer, particularly in Asia-Pacific and North America is boosting the demand for ablation therapies. Tumor ablation is especially beneficial for patients with early-stage liver cancer who are not eligible for surgery. Furthermore, Lung cancer is another significant application area for tumor ablation, particularly for patients with inoperable or recurrent tumors. As healthcare providers increasingly adopt minimally invasive procedures to reduce recovery times and complications, the use of tumor ablation in lung and kidney cancer treatment is expected to rise during the forecast period.

Furthermore, advances in technology are improving the efficacy and precision of tumor ablation techniques. The development of image-guided procedures such as ultrasound and computed tomography (CT) guidance enables more precise tumor targeting, increasing treatment outcomes. As hospitals and clinics engage in updating their facilities with these new technologies, tumor ablation will become more accessible accelerating market growth. Regulatory approvals and clinical research demonstrating the safety and efficacy of these procedures boost confidence among healthcare practitioners and patients, resulting in higher adoption rates.

Country/Region-wise Acumens

Will Advancements in Healthcare Infrastructure Drive the North American Market?

The North American Tumor Ablation Market is projected to remain the largest regional market due to the region's advanced healthcare infrastructure and increasing adoption of innovative technologies. The U.S. leads the market driven by high healthcare spending, a large patient population, and the presence of key industry players. The increasing prevalence of liver, lung, and kidney cancers coupled with rising awareness about minimally invasive treatments is further propelling market growth.

Furthermore, favorable reimbursement policies and ongoing research in tumor ablation technologies are supporting the market in North America. The growing use of image-guided ablation techniques, such as MRI and CT scans to improve precision in tumor targeting is expected to drive further adoption of tumor ablation therapies.

Will Rising Cancer Incidence Fuel the Market in Asia Pacific?

The Asia Pacific region is expected to witness the highest growth in the Tumor Ablation Market due to the rising incidence of cancer and increasing healthcare investments. Countries such as China, Japan, and India are seeing a surge in cancer cases, particularly liver and lung cancer, which is fueling the demand for tumor ablation procedures. Moreover, government initiatives to improve healthcare access and the growing availability of advanced medical technologies are boosting market growth.

The growing adoption of ablation procedures in the Asia Pacific region is also driven by the growing demand for minimally invasive treatments and the rising awareness of their benefits among patients and healthcare providers. As healthcare infrastructure in emerging economies continues to improve, the Tumor Ablation Market is expected to expand significantly in this region.

Competitive Landscape

The Tumor Ablation Market is characterized by a mix of established and emerging players, each focusing on technological advancements, strategic partnerships, and product innovations to maintain a competitive edge. Companies are investing in developing new ablation technologies that offer improved precision, safety, and patient outcomes.

Some of the prominent players in the Tumor Ablation Market include:

Boston Scientific Corporation, Medtronic PLC, AngioDynamics, Inc., Merit Medical Systems, Johnson & Johnson (Ethicon), EDAP TMS S.A., IceCure Medical Ltd., RF Medical Co. Ltd., Neuwave Medical, Inc. (Johnson & Johnson).

Latest Developments

In June 2023, Boston Scientific launched a next-generation microwave ablation system designed to target larger tumors while minimizing damage to healthy tissues.

In October 2022, Medtronic announced its acquisition of an advanced cryoablation technology company to expand its portfolio in tumor ablation treatments.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TUMOR ABLATION MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL TUMOR ABLATION MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY

  • 5.1 Overview
  • 5.2 Radiofrequency Ablation (RFA)
  • 5.3 Microwave Ablation (MWA)
  • 5.4 Cryoablation
  • 5.5 Other Technologies

6 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Liver Cancer
  • 6.3 Lung Cancer
  • 6.4 Kidney Cancer
  • 6.5 Others

7 GLOBAL TUMOR ABLATION MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL TUMOR ABLATION MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Healthtronics, Inc.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Medtronic, PLC.
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Sonacare Medical, LLC
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Boston Scientific Corporation
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Edap Tms S.A.
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Misonix, Inc.
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Galil Medical, Inc.
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Neuwave Medical, Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Mermaid Medical A/S
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Angiodynamics, Inc.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research